Labcorp Holdings INC Form 4 insider transactions

A director at Labcorp Holdings Inc. has sold 500 shares of common stock for $260 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Labcorp Holdings Inc. Executive Vice President Brian J. Caveney reported the sale of 2,000 shares of common stock at $247 per share, executed under a Rule 10b5-1 trading plan.

Adam Schechter, President & CEO of Labcorp Holdings Inc., sold 6,105 shares of common stock at $248.73 per share on May 12, 2025, under a pre-arranged 10b5-1 trading plan.

Sandra van der Vaart, EVP and Chief Legal Officer of Labcorp, reported selling 1,900 shares of common stock on May 1, 2025.

Peter J. Wilkinson, SVP and Chief Accounting Officer of Labcorp Holdings Inc., sold 829 shares of common stock on May 1, 2025.

EVP Megan D. Bailey reports the vesting and subsequent tax withholding of restricted stock units.

EVP and Chief Marketing Officer of Labcorp, Amy B. Summy, reports acquisition and disposal of company stock, including shares acquired through a performance award and sales to cover tax obligations.

Mark S. Schroeder, EVP, Pres Diagnostics & COO of Labcorp Holdings Inc., reports acquisition and disposal of common stock on March 27 and 28, 2025.

Sandra van der Vaart, EVP and Chief Legal Officer of Labcorp, reports acquisition of shares through a performance award and disposition of shares to cover tax obligations.

Adam H. Schechter, President & CEO of Labcorp Holdings Inc., reports acquisition of shares through a performance award and disposition of shares to cover tax obligations.

Executive Vice President Glenn Eisenberg of Labcorp Holdings Inc. reports acquisition of shares through a performance award and disposition of shares to cover tax obligations.

Lance Berberian, EVP at Labcorp, reports acquisition of shares through a performance award and disposition of shares to cover tax obligations.

Brian J. Caveney, an executive at Labcorp Holdings Inc., reported acquiring shares through a performance award and disposing of shares to cover tax obligations.

Peter J. Wilkinson, SVP and Chief Accounting Officer of Labcorp Holdings Inc., reports acquiring shares through a performance award and disposing of shares to cover tax obligations.

A Form 4 filing reveals that Labcorp's EVP, CIO & CTO, Akinbolade Oyegunwa, acquired shares through a performance award and disposed of shares to cover tax obligations.

Director Kerrii B. Anderson sold 500 shares of Labcorp Holdings Inc. on March 5, 2025, at a price of $255.6347 per share.

Labcorp's EVP, Pres Diagnostics & COO, Mark S. Schroeder, exercised stock options and sold a portion of the acquired shares on February 28, 2025, according to a recent SEC filing.

Sandra D. van der Vaart, EVP and Chief Legal Officer of Labcorp, reports the sale of 1,314 shares of common stock on February 25, 2025.

Amy B. Summy, EVP and Chief Marketing Officer of Labcorp, reports the sale of 226 shares of common stock at $250.4 per share on February 24, 2025, under a pre-arranged 10b5-1 trading plan.

Peter J. Wilkinson, SVP and Chief Accounting Officer of Labcorp Holdings Inc., reports stock transactions including option exercise and sale.

Peter J. Wilkinson, SVP, Chief Accounting Officer of Labcorp Holdings Inc., reports acquisition and disposal of common stock and derivative securities.

EVP and Chief Marketing Officer of Labcorp Holdings Inc., Amy B. Summy, reports acquisition and disposal of common stock and derivative securities.

Megan D. Bailey, EVP, Pres, Central Labs & Intl of Labcorp Holdings Inc., reports the acquisition of stock options and restricted stock units.

Labcorp CEO Adam Schechter reports the acquisition and disposal of company stock and derivative securities.

Glenn Eisenberg, Executive Vice President of Labcorp, reports the disposition of shares to cover tax obligations and the vesting of restricted stock units.

EVP Lance Berberian reports the vesting and subsequent tax withholding of Labcorp stock units.

Labcorp's EVP, Brian J. Caveney, reports acquisition and disposal of company stock and stock options.

Sandra D. van der Vaart, EVP and Chief Legal Officer of Labcorp Holdings Inc., reports transactions involving common stock and stock options.

Mark S. Schroeder, EVP, President Diagnostics & COO of Labcorp Holdings Inc., reports acquisition and disposal of common stock and derivative securities.

Anita Z. Graham, EVP, CHRO of Labcorp Holdings Inc., reports the acquisition of stock options and restricted stock units.